References
- Fahn S. Management of Parkinson's disease at different stages of the illness. Clin Neuropharmacol 1982: 5(Suppl 1): S1
- Muenter MD. Initial treatment of Parkinson's disease Clin Neuropharmacol 1982: 5(Suppl 1): S2–12
- Duvoisin RC. Management of patients who fail to respond to levodopa thcrapv Clin Neuropharmacol 1982: 5(Suppl 1): S13–8
- Jancovic J. Management of motor side-effects of chronic levodopa therapy. Clin Neuropharmacol 1982: 5(Suppl 1): S19–28
- Klawans HL. Behavioral alterations and the therapy of parkinsonism. Clin Neuropharmacol 1982: 5(Suppl l): S29–37
- Calne D. The role of various forms of treatment in the management of Parkinson's disease. Clin Neuropharmacol 1982: 5(Suppl 1): S38–43
- Klawans HL. What to do when Sinemet fails: part 1. Clin Neuropharmacol 1984: 7(2): 121–33
- Plum F, ed. The on-off phenomenon in parkinsonism. Neurol Alert 1982: 1(Dec): 4
- Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984: 2(8414): 1262–5
- Koller WC. Propranolol therapy for essential tremor of the head Neurology 1984: 34(8): 1077–9
- Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985: 103: 347–50
- Jancovic J, Ford J. Blepharospasm and orofacial- cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983: 13(4): 402–11
- Spasmodic dysphonia. (Editorial) Lancet 1984: 2(Nov 24): 1192
- Goetz CG, Klawans HL. Drug-induced extrapyramidal disorders—a neuropsychlatric interface. J Clin Psychopharmacol 1981: 1(5): 297–303
- Jeste DV, Wyatt RJ. Tardive dyskinesia. Psichiatric Ann 1980: 10(1): 16–52
- Klawans HL. Tanner CM, Barr A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 1984: 7(2): 153–9